anti-LAG-3 (human) mAb (17B4) (FITC)
| Code | Size | Price |
|---|
| AG-20B-0012F-C100 | 100 ug | £350.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: 17B4
Regulatory Status: RUO
Target Species: Human
Application: Flow Cytometry
Shipping:
+4°C
Storage:
4°C
Documents
Further Information
Alternate Names/Synonyms:
Lymphocyte Activation Gene-3; FDC Protein; CD223
Concentration:
1mg/ml
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. In PBS containing 0.02% sodium azide.
Handling Advice:
Do not freeze.Protect from light.
Immunogen:
Synthetic peptide corresponding to 30 aa in the N-terminus of human LAG-3.
Labels - Conjugates:
FITC
Long Description:
Monoclonal Antibody. Recognizes human LAG-3. Isotype: Mouse IgG1. Clone: 17B4. Applications: FACS. Liquid. In PBS containing 0.02% sodium azide. Lymphocyte activation gene 3 (LAG-3; CD223) plays an important role in negatively regulating T cell proliferation, function and homeostasis. It is required for maximal natural and induced regulatory T cell (Treg) function. LAG-3 is closely related to the T cell co-receptor CD4 and binds to MHC class II molecules but with a significantly higher affinity than CD4.
NCBI, Uniprot Number:
P18627
Package Type:
Plastic Vial
Product Description:
Lymphocyte activation gene 3 (LAG-3; CD223) plays an important role in negatively regulating T cell proliferation, function and homeostasis. It is required for maximal natural and induced regulatory T cell (Treg) function. LAG-3 is closely related to the T cell co-receptor CD4 and binds to MHC class II molecules but with a significantly higher affinity than CD4.
Purity:
>95% (SDS-PAGE)
Source / Host:
Purified from concentrated hybridoma tissue culture supernatant.
Specificity:
Recognizes human LAG-3.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibody Conjugates
UNSPSC Number:
12352203
Use & Stability:
Keep conjugated formats at +4°C. Stable for at least 1 year after receipt when stored at +4°C.
References
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens: E. Baixeras, et al.; J. Exp. Med.176, 327 (1992) | Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand: B. Huard, et al.; Immunogenetics 39, 213 (1994) | Characterization of the major histocompatibility complex class II binding site on LAG-3 protein: B. Huard, et al.; PNAS 94, 5744 (1997) | CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling: S. Hannier, et al.; J. Immunol. 161, 4058 (1998) | T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts: C.E. Demeure, et al.; Eur. J. Cancer 37, 1709 (2001) | Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway: E.D. Carlo, et al.; J. Pathol. 205, 82 (2005) | The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells: L. Macon-Lemaitre and F. Triebel; Immunology 115,170 (2005) | A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors: F. Triebel, et al.; Cancer Lett. 235, 147 (2006) | Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells: J. Bayry, et al.; J. Immunol. 178, 4184 (2007) | Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation: C. Casati, et al.; J. Immunol. 180, 3782 (2008) | Peripheral Tr1 and Foxp3+ Treg as Markers of Recurrent Malignancies in Patients with Hepato-Biliary Pancreatic Cancers: T. Ikemoto, et al.; Anticancer Res. 37, 5541 (2017)